Not available
Quote | Arbutus Biopharma Corporation (NASDAQ:ABUS)
Last: | $2.78 |
---|---|
Change Percent: | -0.73% |
Open: | $2.75 |
Close: | $2.78 |
High: | $2.8 |
Low: | $2.74 |
Volume: | 626,057 |
Last Trade Date Time: | 04/29/2024 03:00:00 am |
News | Arbutus Biopharma Corporation (NASDAQ:ABUS)
2024-04-25 10:05:00 ET Summary Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP returned 6.0% for the First Quarter of 2024. The Fund has annualized returns of 10.0% since inception, compa...
2024-04-23 14:40:54 ET Summary Moderna's stock rose after positive results from its cancer vaccine trial, but legal issues could lead to a massive judgment against the company. Moderna is facing a patent dispute over its use of lipid nanoparticles technology without proper licensi...
Message Board Posts | Arbutus Biopharma Corporation (NASDAQ:ABUS)
Subject | By | Source | When |
---|---|---|---|
$ABUS Arbutus Biopharma Corporation | mick | investorshub | 04/30/2023 11:03:50 PM |
Arbutus Biopharma Corporation (Nasdaq: $ABUS), a clinical-stage biopharmaceutical | mick | investorshub | 04/18/2023 8:07:45 PM |
With a median price-to-sales (or "P/S") ratio of | mick | investorshub | 04/18/2023 8:06:48 PM |
$ABUS Arbutus Biopharma Corporation | mick | investorshub | 04/15/2023 6:42:52 PM |
rare form / https://investorshub.advfn.com/Arbutus-Biopharma-Corporation-17838#: | mick | investorshub | 04/15/2023 6:42:33 PM |
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leve...
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it...